Clinical Study
Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer
Table 2
Immunoreactivity of the 14F7 Mab in normal tissue and lung carcinoma samples.
| |||||||||||||||||||||||||||||||||||||||||||||||
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%). |